Seeking Alpha
 

Johnson & Johnson (JNJ)

- NYSE
  • Sep. 18, 2012, 5:26 PM
    JNJ's Janssen Biotech unit requests FDA approval of Simponi, its investigational intravenous formulation for the treatment of adults with moderately to severely active rheumatoid arthritis.
    | Comment!
  • Sep. 13, 2012, 11:23 AM
    The FDA issues a warning that some consumers have reported receiving serious skin injuries while using certain over-the-counter mild muscle and joint pain relievers containing the active ingredients menthol, methyl salicylate and capsaicin. 43 reported cases of burns have been reported, with the injuries ranging from mild to severe chemical burns. Some of the products named include Sanofi's (SNY -0.1%) Icy Hot and Johnson & Johnson's (JNJ +0.7%) Bengay, among others.
    | 2 Comments
  • Sep. 13, 2012, 9:01 AM
    Johnson & Johnson (JNJ) hires Bayer CropScience CEO Sandra Peterson to oversee J&J's recall-plagued consumer health and manufacturing operations. Peterson's recruitment is the first major executive hire by Alex Gorsky since he became J&J CEO in April as he looks to make good on a pledge to fix the company's quality, legal and ethical problems. (PR)
    | 3 Comments
  • Sep. 12, 2012, 9:35 AM
    J&J's (JNJ) and Pfizer' (PFE) bapineuzumab drug showed signs that it is able to reduce nerve-cell damage in the brain and the buildup of amyloid plaque, which has been linked to Alzheimer's disease. While bapineuzumab was unable to improve patients' memory or thinking, as disclosed last month, the drug could eventually be used as a preventative measure.
    | 1 Comment
  • Sep. 5, 2012, 8:21 AM
    The FDA grants priority review status for Johnson & Johnson's (JNJ) bedaquiline drug, which is a treatment for strains of tuberculosis that are resistant to other multiple drugs. The FDA is expected to decide on bedaquiline in early 2013 after J&J filed for approval in June.
    | Comment!
  • Aug. 30, 2012, 12:27 PM
    J&J's (JNJ -0.5%) Janssen Pharmaceuticals settles with 36 states and the District of Columbia regarding allegations related to promotional and marketing practices for its anti-psychotic medication Risperdal. Under the terms of the agreement, the company will pay approximately $181M, with predesignated portions to be paid to each state participating in the settlement.
    | Comment!
  • Aug. 30, 2012, 8:16 AM
    J&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab from Danish biotech Genmab in a deal that could eventually be worth over $1.1B. Janssen is paying $55M upfront and will make further payments following the achievement of development, regulatory and sales milestones. J&J is also investing $80M in Genmab in return for a 10.7% stake. (PR)
    | Comment!
  • Aug. 27, 2012, 10:02 AM
    J&J's (JNJ +0.2%) and Bayer's (BAYRY.PK) Xarelto blood thinner significantly cut cardiovascular death, heart attacks and strokes in patients who have suffered a severe heart attack and when used with with standard treatments. The results came from  a Phase III trial that was testing Xarelto for use in acute coronary syndrome, for which the companies are trying to receive FDA approval after a rejection in June. (PR)
    | Comment!
  • Aug. 27, 2012, 8:38 AM
    Medtronic's (MDT) Protect study confirms the long-term safety of drug-eluting coronary stents, which slowly release a drug to block cell proliferation. The trial, the largest ever for such products, used Medtronic's Endeavor stent and J&J's (JNJ) Cypher to test for stent thrombosis, when a blood clot forms inside the stent. (PR)
    | 4 Comments
  • Aug. 23, 2012, 9:35 AM
    GSK and J&J (JNJ) start Phase III trials of sirukumab for treating moderate-to-severe rheumatoid arthritis. Sirukumab is among a number of drugs under development for the multi-billion dollar market for treating RA, which affects 1.5M Americans and 23.5M people globally. (PR)
    | Comment!
  • Aug. 21, 2012, 2:20 PM
    The U.S. saw the birth rate fall to its lowest level since the depths of World War II, cutting into consumption numbers and spending totals. The population only increased by 0.92% over the most recent tracking period from the Census Bureau and the number of births actually declined last year. Though a growing percentage of career-focused working women factors in, a sluggish U.S. economy has been the biggest influence on the nation's birth rate. Feeling the baby blues: PG, KMB, JNJ, HAS.
    | 13 Comments
  • Aug. 21, 2012, 8:06 AM
    Johnson & Johnson (JNJ) agrees to pay a total of $600K to resolve three lawsuits over problems caused by its defective ASR hip implants, Bloomberg reports. The cases are the first out of around 8,000 lawsuits to be settled, with J&J facing a bill of up to $2B. The company has already spent $800M on recalls in the past two years.
    | 1 Comment
  • Aug. 20, 2012, 8:40 AM
    Pharmacyclics' (PCYC) Phase II trial of its ibrutinib drug in patients with mantle cell lymphoma, a rare type of non-Hodgkin's lymphoma, enrolls its 5th patient, thereby triggering a second milestone payment of $50M from J&J (JNJ) unit Janssen Biotech. Additional $50M payments could be triggered up to a total of $250M. (First payment)
    | 2 Comments
  • Aug. 14, 2012, 4:41 PM
    Louis Bacon's Moore Capital - recently making headlines for returning $2B to investors as it can't figure out how to create alpha anymore - sells $700M worth of stocks, including all of its holdings of JPMorgan, Wells Fargo, U.S. Bancorp, an Emerging Market ETF (VWO), and Williams Companies (WMB). The fund took new positions in HYG, JNJ, AGO, and troubled Diamond Foods (DMND).
    | 5 Comments
  • Aug. 14, 2012, 4:40 PM
    Warren Buffett's new positions, according to Berkshire's (BRK.A, BRK.B) latest 13-F, include 27.1M shares of Phillips 66 (PSX) and 2.8M shares of National Oilwell Varco (NOV), but he dumped his entire 7.7M-share position in Intel (INTC) and sold two-thirds of his 29M shares in Johnson & Johnson (JNJ).
    | 36 Comments
  • Aug. 8, 2012, 9:03 AM
    While Pfizer's (PFE) and J&J's (JNJ) bapineuzumab Alzheimer's drug failed in a Phase III trial of people who already exhibit symptoms, scientists may yet test it on those at risk of the disease but aren't yet affected. Pfizer and J&J, though, don't yet have plans to assess bapineuzumab for this purpose.
    | 2 Comments
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.